Drugs / Activated T-Lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04018261 | Jul 2019 → Oct 2021 | cytomegalovirus infection, immunodeficiency-related disorder | Blood and Tissue Bank of Catalonia | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Activated T-Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04018261 ↗ |
| Route | Intravenous | “Activated T-Lymphocytes will be infused intravenously in a single-dose” NCT04018261 ↗ |